anti-Neurosin, mAb (9A7)

CHF 315.00
In stock
YIF-LF-MA0153100 µlCHF 315.00
More Information
Product Details
Synonyms Zyme; KLK6; SP59; PRSS18; Neurosin; Protease M; EC=3.4.21.-; Kallikrein-6; Serine Protease 9; Serine Protease 18
Product Type Monoclonal Antibody
Clone 9A7
Isotype Mouse IgG1 κ
Immunogen/Antigen Recombinant human protein purified from E. coli.

Western Blot (1:1,000)

Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Isotype Negative Control

Mouse IgG1 Isotype Control

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Kallikreins (KLKs) belong to the serine protease family of proteolytic enzymes. Neurosin (KLK6), one of these, is atrypsin-like protease dominantly expressed in the human brain but also in a variety of other tissues. As measured by a sensitive quantitative assay in serum and cerebrospinal fluid(CSF), it may have value as a biomarker for diagnosis and monitoring of Alzheimer's disease (AD). It seems to be down regulated in serum and tissues of AD patients and may be involved in amyloid metabolism. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen. Degrades α-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis.

Product References

1) Akira O, et. al. Neurochemistry (2001) vol.12(7) pp.1345 -50. (General)
2) George M, et. al. Clinica Chimica Acta (2003) vol.329, pp.1-8. (General)
3) Georgios P, et. al. BBRC (2004) vol.320 pp.54-61. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.